Plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to peripheral blood for collection and autologous transfusion in patients with lymphoma or multiple myeloma.

Plerixafor reversibly blocks the chemokine receptor CXCR4 to prevent binding of its ligand CXCL12 (stromal cell-derived factor-1α).

The drug is injected after four days of treatment with granulocyte-colony stimulating factor (G-CSF), 6-11 hours before initiation of apheresis. Following administration, both haematopoietic progenitor cells and mature leukocytes appear in the systemic circulation.

View Mozobil drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...